- Company
- Imjudo is expected to be introduced in Korea
- by Eo, Yun-Ho Nov 23, 2022 06:03am
- Another immuno-cancer drug with CTLA-4 inhibitory mechanism is expected to be introduced in Korea. According to related industries, AstraZeneca Korea has submitted an application for domestic permission for CTLA-4 inhibitor Imjudo, a partner in combination therapy for PD-L1 inhibitor Impinzi. The combination therapy of Impinzi and Imjudo was
- Company
- Attention focused on whether Luxturna will be reimb in Korea
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Discussions on expanding coverage of the one-shot gene therapy ‘Luxturna’ is not making much progress. Therefore, the industry’s eyes are on whether Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation by the Health Insurance Review and Assessmen
- Company
- GSK Duodart can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Duodart, a prostate hypertrophy compound, has settled in general hospitals. According to related industries, GSK Korea's Duodart recently passed DC of Big 5 General Hospitals such as Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital. This drug has been applied to insurance benefits
- Company
- Evrysdi can be prescribed with non-reimbursement
- by Eo, Yun-Ho Nov 21, 2022 05:56am
- Evrysdi, an eating spinal muscular atrophy treatment, can be prescribed at hospitals and is still non-reimbursement. According to related industries, Roche Korea's Spinal Muscular Atrophy treatment passed through D.C. at medical institutions such as Severance Hospital, Seoul National University Hospital, Yangsan Pusan National University Hosp
- Company
- Dong-AST ended the clinical trial of Stelara biosimilar
- by Chon, Seung-Hyun Nov 21, 2022 05:56am
- Dong-AST announced on the 17th that the global phase 3 clinical trial of Stella biosimilar DMB-3115 has ended. Phase 3 of global clinical trials of DMB-3115 was conducted for 52 weeks in a total of 605 patients in 9 countries, including Poland, Estonia, and Latvia, starting in the United States in 2021. Phase 3 of this global clinical trial w
- Company
- KPBMA visits Boston...expands exchanges with MIT, etc.
- by Chon, Seung-Hyun Nov 18, 2022 06:04am
- On the 17th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) announced that its delegation had visited Boston, US to network with local companies and institutions. Hee-Mok Won, Director of KPBMA, Sung-Tae Yoon, Chairman of KPBMA, and other representatives of Korea’s pharmaceutical and bio business attended the exec
- Company
- Generic companies won 9 out of 10 patent disputes
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- In a patent dispute between the original company and the generic company over generic for exclusivity, a study found that the generic company's first trial winning rate reached 88.5%. Lee Myung-hee, a senior researcher at the KIIP, announced the results of the impact assessment of the licensing patent-linked system at the 2022 Pharmaceutic
- Company
- Announcement of commercialization of oral insulin
- by Eo, Yun-Ho Nov 17, 2022 05:54am
- Expectations are rising for PO use for injectable insulin. Medicox recently signed an exclusive distribution contract with Israeli pharmaceutical company Oramed Pharmaceuticals following the introduction of oral insulin technology. As a result, Medicox will be able to distribute Oramed's oral insulin candidate "ORMD-0801" for 10 years in Kore
- Company
- The aftermath of stricter generic regulations?
- by Kim, Jin-Gu Nov 16, 2022 06:11am
- It was found that the number of applications for generic for exclusivity decreased sharply. Experts agree that the implementation of the 1+3 system has affected the decrease in the number of generic for exclusivity applications. Lee Myung-hee, a senior researcher at KIIP, introduced the number of generic for exclusivity applications in 2020 a
- Company
- Gavreto applies for reimbursement following Retevmo
- by Eo, Yun-Ho Nov 16, 2022 06:10am
- In line with the progress made in Retevmo’s reimbursement review process, its competitor Gavreto was also found to have started its reimbursement process in Korea. According to industry sources, Roche Korea submitted an application for the reimbursement of its RET (Rearranged during transfection) gene fusion targeted therapy Gavreto (pr
